VentureMed Drives Expansion and Clinical Evidence Growth
VentureMed Group, Inc. is recognized as a leading innovator in medical devices focused on treatments for arteriovenous (AV) access and peripheral arterial disease (PAD). With an ambition to build upon its market influence, the company has broadened its commercial leadership team, aiming to boost growth significantly. A pivotal development in reinforcing their clinical stance includes a recent peer-reviewed study published in the Journal of Endovascular Therapy, highlighting the compelling clinical advantages of the FLEX Vessel Prep™ System combined with drug-coated balloons.
Strategic Leadership Enhancements to Propel Growth
The newly expanded leadership group at VentureMed is set to target several vital strategic objectives:
- Increasing the market presence of the FLEX Vessel Prep™ System within the United States and selected European regions.
- Improving reimbursement strategies in the U.S. to promote product adoption and ensure sustained market viability.
- Expanding manufacturing capabilities to cater to growing market demand.
In light of this growth initiative, VentureMed has appointed accomplished professionals into key positions to spearhead these strategic directions:
- Dr. Jordan Knepper, MD, MSc, a vascular surgeon and Associate Professor of Surgery, steps in as Chief Medical Officer, succeeding Dr. John Pigott, who continues as Founder & Critical Advisor.
- Pete Theirl becomes the Vice President of Global Sales, leveraging his extensive background in medical device sales focused on peripheral interventions.
- Tom Michals takes on the role of Vice President of Marketing, utilizing his rich experience from prominent companies like Boston Scientific and Medtronic.
- Bruce Werner joins as Senior Director of Sales Operations & Customer Fulfillment, emphasizing commercial execution and customer success.
Moreover, existing team members Dave Michaelson and Kathy Leith will transition into the roles of VP of U.S. Sales and VP of Market Access and Reimbursement, respectively.
Augmenting Clinical Data to Support FLEX VP™ Systems
A noteworthy investigator-led study conducted by Dr. Daniel Periard has been published, titled "The Benefit of Longitudinal Micro-incisions Prior to Paclitaxel-Coated Balloon Angioplasty". This single-arm prospective trial involving 41 patients recorded a remarkable 97.5% freedom from clinically driven target lesion revascularization (CDTLR) and demonstrated sustained symptom relief at the 12-month follow-up. These insights point to significant long-term patient benefits when using the FLEX Vessel Prep™ System alongside drug-coated balloons, particularly for patients with intricate calcified lesions.
Optimizing Position for a Successful Year
Denis Harrington, President & CEO of VentureMed Group, affirmed, "Our robust leadership team, combined with expanding clinical evidence, positions us ideally to enhance the adoption of the FLEX Vessel Prep™ System and reach our focused sales objectives this year." This strong positioning sets the stage for VentureMed's ambitious plans ahead.
About VentureMed Group & the FLEX Vessel Prep™ System
VentureMed Group, Inc. specializes in developing cutting-edge medical devices aimed at improving endovascular interventions for arteriovenous (AV) access and peripheral arterial disease (PAD). The flagship product, the FLEX Vessel Prep™ System, employs proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology to enhance vessel preparation. Unlike traditional approaches utilizing static pressure, KEMIC utilizes controlled motion to generate precise micro-incisions within the vessel walls.
This advanced mechanism has been shown to facilitate luminal gain, potentially improve drug absorption when applied in combination therapies, and minimize vessel trauma, thereby decreasing the likelihood of restenosis. With FDA 510(k) clearance and CE Mark approval, FLEX is setting a new benchmark in vessel preparation and optimizing treatment pathways for patients on a global scale.
For more information about VentureMed Group and its innovative solutions, visit www.VentureMedgroup.com.
Media contact: Kathy Leith
(763-296-2026)
Frequently Asked Questions
What is the main focus of VentureMed Group?
VentureMed Group specializes in medical devices for arteriovenous (AV) access and peripheral arterial disease (PAD).
What is the FLEX Vessel Prep™ System?
The FLEX Vessel Prep™ System is a pioneering technology designed to enhance vessel preparation during endovascular procedures.
Who are the new key appointments in the leadership team?
Recent additions include Dr. Jordan Knepper as Chief Medical Officer and Pete Theirl as Vice President of Global Sales.
How does the clinical evidence support the FLEX Vessel Prep™ System?
Recent studies show significant long-term benefits in patient outcomes utilizing the FLEX system during interventions.
What is the company's vision for the upcoming year?
VentureMed aims to boost adoption of its FLEX Vessel Prep™ System and reach specific sales goals through robust leadership and clinical evidence.
